Lupus Research Alliance (LRA), the world’s largest private funder of lupus research, in collaboration with Genentech, a member of the Roche Group, announced the inaugural recipients of
Read Article
Xu et al. from Shanghai University have written an analysis of global lupus nephritis (LN) clinical trials and call for innovation.
Read Article
UCB has released the Week 16 results from BE BOLD trial that will be presented at EULAR 2026 in London on Saturday, June 6. This head-to-head trial demonstrates that at week 16, bimekizumab (BKZ) yielded superior ACR50 results compared to risankizumab (RKB) adults with active psoriatic
Read Article
Plasmacytoid dendritic cells (pDCs) have been strongly implicated in the pathogenesis of lupus, as their primary product, type I interferon, drive systemic lupus erythematosus and cutaneous lupus erythematosus. A recent comprehensive review synthesizes the available data on pDCs, and,
Read Article
Palindromic rheumatism may develop rheumatoid arthritis (RA) and could be an at-risk population. A pilot trial compared abatacept (ABA) versus hydroxychloroquine and demonstrated ABA reduces RA development in a 2 year study.
An open-label, multicenter, randomized trial enrolled 70
Read Article
Dr. Jack Cush discusses his favorite journal articles from the past week on RheumNow.com.
Read Article
A current review of eosinophilic granulomatosis with polyangiitis (EGPA) provides current recommendations on diagnosis and management.
Read Article
Enpatoran, an investigational oral drug that inhibits Toll-like receptors (TLR) 7 and 8, was superior to placebo in relieving lupus skin manifestations in a dose-finding phase II trial.
Read Article
A new review on Toll-like receptors (TLRs) systematically summarizes forty years of discoveries in the TLR field, from the initial identification of Toll in Drosophila embryonic development to the current understanding
Read Article
A current article in Nature Reviews Rheumatology has a patient boldly asking why we rheumatologists aren't more like her oncologists?
Read Article
For decades, the standard of care in rheumatology has been combination therapy - pairing methotrexate (MTX) with an advanced biologic or synthetic agent to achieve optimal outcomes.
Read Article
Drugs commonly used to treat systemic autoimmune rheumatic diseases (SARDs) may keep the SARS-CoV-2 circulating after COVID-19 infection in patients with these conditions, with researchers documenting substantially increased viral antigen persistence compared with other post-COVID patients.
Read Article
Malignancy rivals cardiovascular disease as a leading cause of death in patients with systemic autoimmune diseases. Chronic inflammation and immune dysregulation can drive oncogenesis, while antitumor immune responses can trigger autoimmune phenomena (paraneoplastic syndromes, checkpoint
Read Article
Dr. Jack Cush follows the money and all the news that fits the Rheumatology Gab for this past week.
Read Article
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Read Article
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
